Recent News

• 01.28.2026 - GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
• 01.26.2026 - GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
• 01.21.2026 - GRI Bio Announces Reverse Stock Split
• 12.12.2025 - GRI Bio Announces Closing of $8.0 Million Public Offering

Recent Filings

• 01.28.2026 - EX-99.1 EX-99.1
• 01.28.2026 - 8-K Current report
• 01.21.2026 - 8-K Current report
• 01.21.2026 - EX-99.1 EX-99.1
• 01.16.2026 - 8-K Current report
• 01.15.2026 - 8-K Current report
• 01.09.2026 - EX-99.1 EX-99.1
• 01.09.2026 - 8-K Current report
• 01.09.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.08.2026 - EX-99.1 EX-99.1